MeSH D006467 - hemophilia a
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Roche | Emicizumab | Hemlibra |  | 2018-02-23 | $4,779.09 M | Q4/22-Q3/23 |
| Bayer | Octocog alfa | Helixate NexGen |  | 2000-08-04 |  |  |
| Octocog alfa | Iblias |  | 2016-02-18 |  |  | |
| Octocog alfa | Kogenate Bayer |  | 2000-08-04 |  |  | |
| Octocog alfa | Kovaltry |  | 2016-02-18 |  |  | |
| Pfizer | Nonacog alfa | BeneFIX |  | 1997-08-27 | $424 M | Y2023 |
| Moroctocog alfa | ReFacto |  | 1999-04-13 | $230 M | Y2023 | |
| Takeda | Octocog alfa | Advate |  | 2004-03-02 |  |  |
| Genentech | Emicizumab | Hemlibra |  | 2017-11-16 |  |  |
| Orphan Medical | Efmoroctocog alfa | Elocta |  | 2015-11-18 |  |  |
| Novo Nordisk | Turoctocog alfa | Esperoct |  | 2019-06-20 |  |  |
| Turoctocog alfa | NovoEight |  | 2013-11-13 |  |  | |
| Eptacog alfa (activated) | NovoSeven |  | 1996-02-23 |  |  | |
| BioMarin Pharmaceutical | Valoctocogene roxaparvovec | Roctavian |  | 2023-06-29 | $1.671 M | Q3/23-Q1/24 |
| CSL Behring | Lonoctocog alfa | Afstyla |  | 2017-01-04 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
86%19/22
Phase 2
91%20/22
Phase 3
83%29/35
Approved: 14Overall Success rate: 65%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use